

Pharmacogenomics

Session 1 OPENING SESSION

WEDNESDAY 11/15/2006, 7:30 PM

R.M. Weinshilbourn / J.S. Leeder

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
1	Giacomini	The Pharmacogenetics Research Network—From SNP discovery to clinical drug response	25
2	Nakamura	"BioBank Japan"—Toward the personalized medicine	25
3	Collins	Genomic power tools for common disease and pharmacogenomics	25

Session 2 GLOBAL PHARMACOGENOMICS RESEARCH AND DATABASE

THURSDAY 11/16/2006, 9:00 AM

K. Giacomini / H.Z. Ring

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
4	Pirmohamed	Recent initiatives in pharmacogenetics in the UK	25
	Hayden	TITLE ONLY: Genotype-specific approaches to therapy in children—The GATC Project in Canada	25
5	Suarez-Kurtz	Pharmacogenetics in admixed populations—The case of Brazil	25
6	Altman	PharmGKB—Generating knowledge from literature to catalyze pharmacogenomic research	25
7	Gurwitz	A call for data-sharing in pharmacogenomics	25
8	Cotton	The Human Variome Project—Collection of human genome variation	25

Session 3 RECENT ADVANCES IN GLOBAL PHARMACOGENOMICS RESEARCH

THURSDAY 11/16/2006, 2:00 PM

K. Giacomini / H.Z. Ring

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
9	Wolf	Population pharmacogenetics—A new paradigm for pharmacogenetic studies—The Scottish experience	25
10	Eichelbaum	Individualization of drug therapy by genotype based dosage regimen	25
11	Kennedy	Pharmacogenetics and genomics "down under"—Focus on asthma, inflammatory bowel disease and major depression	25
	Jimenez-Sanchez	Developing a platform for pharmacogenomics in Mexico	25
12	Shin	Genetic and environmental factors in the ethnic difference of drug disposition	25

Session 4 POSTER SESSION I and WINE & CHEESE PARTY

THURSDAY 11/16/2006, 5:00 PM

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
13	Abla	Functional analysis of non-synonymous variants of the multidrug resistance protein 4 (MRP4)	
14	Akiva	Genome-wide INDEL genotyping in human	
15	Almeida	Investigation of the sensitivity and specificity of the <i>HLA-B*5701</i> genotyping assay	

16	Alzahrani	HMG CoA reductase gene single nucleotide polymorphisms and response to simvastatin in patients of Saudi origin
17	Phillips	Pharmacogenomics—Bridging the gap between research and the clinical setting
18	Brown	High-throughput profiling of haplotypes associated with Warfarin dose
19	Pirmohamed	Molecular and genetic association of the human interleukin 6 gene with tacrine-induced transaminitis
20	Cho	Thymidylate synthase (<i>TYMS</i>) and dihydropyrimidine dehydrogenase (<i>DPYD</i>) polymorphisms in the Korean population—For prediction of 5-fluorouracil, associated toxicity
21	Cho	Genetic polymorphism of <i>NAT2</i> and <i>CYP2E1</i> and anti-tuberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis
22	Cho	Association of <i>VKORC1</i> and <i>CYP2C9</i> polymorphisms with Warfarin dose in a Korean patient population
23	Duroudier	Atopy and cysteinyl leukotriene receptor 1 polymorphisms in the British 1958 birth cohort
24	Earthrowl	Identification of variation associated with drug response to Warfarin by exon sequencing
25	Erdelyi	Association of ABC-transporter gene polymorphisms with the incidence of acute toxic encephalopathy in childhood acute lymphoblastic leukemia
26	Erdelyi	Association of ABCB1 and ABCG2 polymorphisms with the immunosuppressive side effect of chemotherapy in childhood acute lymphoblastic leukemia
27	Gaudreault	Development of a focused pharmacogenomics panel for use in hypertension
28	Hansen	The analysis of the relation between antidepressant targets and the hypotheses of depression leads to new pharmacogenetic targets
29	Shuldiner	Correlates and heritability of aspirin resistance
30	Ishikawa	Copy number variation of the drug associated genes
31	Jaja	Is a genetic test for malignant hyperthermia ready for prime time?—Evaluation of the ryanodine receptor (<i>RYR1</i>) gene mutation test
32	JEONG	Association between second intron VNTR region of serotonin transporter gene and major depressive disorder in Korean patients
33	Kallassalu	Human thiopurine methyltransferase allele frequencies in Estonian population and compared to other European populations
34	Kouskoumvekaki	Chemoinformatics—Prediction tools for drug discovery and their impact on pharmacogenomics research
35	Krajcinovic	Leukemia pharmacogenetics—Evidence for 3-way interaction among genes of the folate cycle
36	Xiao	Analysis of the global gene expression profile in mammalian cells derived from patients with Gaucher disease
37	Lamba	Basal CYP3A4 expression may be regulated by a highly interrelated network of multiple liver enriched transcription factors
38	Song	Genetic polymorphisms of human OAT1 and OAT2 genes in a Korean population

39	Lee	Genetic variations of ABC transporters associated with adverse drug reactions of anti-epileptic medications
40	Lee	Genetic polymorphisms of <i>CYP3A4</i> in a Korean population—Effect of <i>CYP3A4+18</i> , the most frequent coding variant in Koreans, on the midazolam pharmacokinetics
41	Leontiev	Fitness associated coinfection in HIV
42	Limdi	The pharmacogenetic optimization of anticoagulation therapy (POAT)—Influence of <i>CYP2Cp</i> genotype on the risk of major hemorrhagic complications in anticoagulated patients on Warfarin during prospective follow up
43	Lorenzi	Asparagine synthetase as a casual, predictive biomarkers for L-Asparaginase activity in ovarian cancer cells

Session 5 FUNCTIONAL GENOMICS AND MODEL SYSTEMS

FRIDAY 11/17/2006, 9:00 AM

H. Jacob / C.R. Wolf

#	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
44	Jacob	Building better models for toxicity and efficacy testing	25
45	Hildebrandt	Microarray analysis of individual and ethnic specific variation in lymphoblastoid cell line gene expression	25
46	Huang	Genes contributing to differences in daunorubicin-induced cytotoxicity in cell lines derived from CEPH and the Yoruban populations	25
47	Ikediobi	Mutation analysis of twenty-four known cancer genes in the NCI-60 cell line set	25
48	Li	Thiopurine S-methyltransferase (TPMT) pharmacogenomic mechanisms—Yeast genomics as a discovery system	25
49	Yang	Cross-species sequence comparison identifies a key control region for cardiac ion channel expression	25

Session 6 TRANSLATIONAL PHARMACOGENOMICS I

FRIDAY 11/17/2006, 2:00 PM

A. Hattersley / M. Pirmohamed

#	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
50	Hattersley	Using pharmacogenetics in diabetes	25
51	Litonjua	Genetic predictors of response to inhaled albuterol in asthma	25
52	Damcott	Genetic variation in the cyclooxygenase-1 (<i>COX1</i>) gene is associated with thromboxane levels in women treated with aspirin	25
53	Pacanowski	β_1 -adrenergic receptor polymorphisms and antihypertensive treatment outcomes in the international verapamil SR/trandolapril study—Genetic substudy (INVEST-GENES)	25
54	Palmer	Target-based population pharmacogenetics of lipid lowering with statins	25
55	Lewis	The role of regulatory agencies in the translation of pharmacogenetics to the clinic	25

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
56	MacPhee	Drugs sharing common routes of metabolism and clearance may not be subject to the same pharmacogenetic influences—A lesson from the calcineurin inhibitors	
57	Mangravite	Simvastatin exposure in human B-cell lymphocytes as a model to explore pleiotropic effects of statin therapy	
58	Thompson	Association of Torsades de Pointes with novel and known SNPs in LQTS genes	
59	Manolopoulos	Frequencies of renin-angiotensin system gene polymorphisms in healthy subjects and coronary artery disease and heart valve disease patients in the Greek population	
60	Manolopoulos	Pharmacogenomics in diagnostic and clinical practice—A European perspective	
61	Mellado	Bradykinin receptor and angiotensin converting enzyme polymorphisms in enalapril-induced cough	
62	Desta	Preliminary assessment of CYP2C19 activity in healthy volunteers by [¹³ C]-PTZ breath test	
63	Mongrain	Development of clinical pharmacogenomics panels for CVD risk assessment using high throughput technologies	
64	NIU	SNP discovery of voltage-gated calcium channel β 2 subunit	
65	Warnich	Molecular genetic analysis of HIV antiretroviral therapy response in South Africa	
66	Polisecki	Polymorphisms and response to pravastatin in the PROSPER study	
67	Price	Liver X receptor- α (LXRA) gene polymorphism and variable CRP response to statins	
68	Promso	Population stratification in four subpopulations of Thailand—Implications for pharmacogenetic studies	
69	Pushpakom	Pharmacogenetic profiling of GISTs in clinical service—Aiding diagnosis and predicting imatinib response	
70	Wadelius	Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes	
71	Ranade	Pharmacogenetic analysis reveals a new role for resistin in HIV lipodystrophy	
72	Renaud	Bioinformatic tool development to improve data accuracy and quality control in high throughput GLP pharmacogenomic studies	
73	Rieder	Association of a single gamma-glutamyl carboxylase (GGCX) polymorphism with Warfarin dosing	
74	Ross	GATC project—A national Canadian active surveillance network to study the pharmacogenomics of severe adverse drug reactions in children	
75	Ryu	Association of polymorphisms of ATM and survival in non-small cell lung cancer patients treated with platinum combination	
76	Saab	Buccal cell DNA extraction—Yield, purity, and cost a comparison of two methods	
77	Seguin	Human genomic variation—Implications for global health	

78	Snitker	Pharmacogenomics of rosiglitazone
79	Spiridou	Supporting personalized medicine with genome resequence data in Ensembl
80	Tantisira	Asthma pharmacogenetics—A novel steroid response gene identified via a family-based screening approach
81	Tatsuno	Screening of genetic variations influencing chemosensitivity of anticancer drugs using lymphoblastoid cell line panel
82	Altman	PharmGKB—Integrating data on genotypes and phenotypes to catalyze pharmacogenomic research
83	Warnich	An evaluation of predisposition to tardive dyskinesia (TD) in Xhosa schizophrenia patients by molecular analysis of variants in <i>CYP1A2</i> and <i>CYP17a-Hydroxylase</i>
84	van Wieren - de Wijer	Interactions between the Gly460Trp α -adducin gene variant and diuretics and the risk of myocardial infarction among treated hypertensive patients
85	Wadelius	Association of Warfarin dose with genes involved in its action and metabolism
86	Welder	Influence of <i>CXCL5</i> polymorphisms on blood pressure in adults without cardiovascular disease
87	Woodahl	Influence of genetic polymorphisms in <i>ABCB1 (MDR1)</i> and <i>CYP3A5</i> on the incidence of acute renal failure and chronic kidney disease after myeloablative hematopoietic cell transplantation
88	Yamada	Pharmacogenetic analysis of an isoniazid metabolism gene, <i>N</i> -acetyltransferase 2
89	Cho	Identification of null allelic variant of cytochrome p450 2C8 in a Korean population
90	Pirmohamed	<i>CD28, CTLA-4, ICOS</i> and <i>PD1</i> genes and carbamazepine-induced hypersensitivity
91	Zhong	One simple step for simultaneously genotyping SNPs, two-adjacent SNPs, small deletion/insertion, and microsatellite repeat polymorphisms for pharmacogenomic tests

Session 8 GENOME-WIDE APPROACHES

SATURDAY 11/18/2006, 9:00 AM

D. Nickerson / J. Hirschhorn

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
92	Hirschhorn	Genome-wide association studies for complex genetic traits	25
93	Onel	The discovery of susceptibility loci for secondary leukemia by genome-wide scan	25
94	Shukla	A genome-wide approach to finding determinants of susceptibility to chemotherapeutic agents	25
95	Nelson	Development and evaluation of genome-wide strategies to identify pharmacogenetic contributions to adverse drug reactions	25
96	Duan	Exon-level dissection of the cis-acting expression quantitative trait loci in human genome	25
97	Lunshof	Genetic secrecy revisited—Consenting to disclosure	25

Session 9 TRANSLATIONAL PHARMACOGENOMICS II

SATURDAY 11/18/2006, 2:00 PM

D. Flockhart / M. Eichelbaum

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
----------	--------------	--------------	--------------------

98	Flockhart	Pharmacogenetics of tamoxifen metabolism and effect in the treatment of breast cancer	25
99	Goetz	The impact of cytochrome p450 2D6 pharmacogenomics in women receiving adjuvant tamoxifen	25
100	Leeder	Evaluation of a [¹³ C]-DM breath test to determine CYP2D6 phenotype	25
101	Coulthard	Methylthioadenosine phosphorylase influence on the cytotoxicity of inhibitors of de novo purine synthesis	25
	Wolf	TITLE ONLY: Polymorphisms in DMEs and cytoprotective genes modify disease risk in patients With pre-malignant adenomas and colorectal cancer	25
102	Xue	Development of an extensive ADME marker panel for pharmacogenetic investigation	25

